Allegro Diagnostics to Present Clinical Trial Results of BronchoGen™ Genomic Test to Improve Diagnosis of Lung Cancer in Late-Breaking Abstract Session at CHEST 2012

Published: Aug 27, 2012

MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen™ genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the Company’s molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect signs of lung cancer. CHEST 2012 is the 78th annual meeting of the American College of Chest Physicians and is being held at the Georgia World Congress Center in Atlanta, October 20-25, 2012.

Back to news